NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Should l Buy ?
Source: PRnewswire
Merger Approval: NLS Pharmaceutics Ltd. shareholders have approved the merger with Kadimastem Ltd., clearing the final corporate hurdle for the formation of NewCelX Ltd.
Future Plans: The combined company is set to be listed on Nasdaq under the ticker "NCEL," pending final approval, marking a significant step in establishing a transatlantic biopharma leader.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
